A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and /or refractory surgical infections in the surgical and gynecological fields.
|ジャーナル||Japanese Journal of Chemotherapy|
|出版ステータス||Published - 1997|
ASJC Scopus subject areas